Summer Sale
50% off Premium Yearly
Novozymes A/S ADR (NVZMY-PK)
Financials 
Technical Analysis 
This is an industrial enzymes company, spun out of Novo Nordisk. It has been a solid performer with a good balance sheet. The problem is that there are rarely good buying opportunities. It trades at a high earnings multiple and rarely misses earnings estimates, for example. This would be a good company to buy in a recession.
- «
- ‹
- 1
- ›
- »
Novozymes A/S ADR (NVZMY-PK) Frequently Asked Questions
What is Novozymes A/S ADR stock symbol?
Novozymes A/S ADR is a OTC stock, trading under the symbol NVZMY-PK on the undefined (undefined). It is usually referred to as or NVZMY-PK
Is Novozymes A/S ADR a buy or a sell?
In the last year, no analyst issued a Buy, Sell, or Hold rating on NVZMY-PK on Stockchase. Read the latest expert commentary for Novozymes A/S ADR .
Is Novozymes A/S ADR a good investment or a top pick?
Novozymes A/S ADR was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Novozymes A/S ADR .
Why is Novozymes A/S ADR stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Novozymes A/S ADR .
Is Novozymes A/S ADR worth watching?
Novozymes A/S ADR is covered by Stockchase experts and is worth watching.
Are merging with another Danish company which will remake the company because it gets them into the biologics industry. The street didn't like the price they were paying at first, but the deal offers growth. Shares have been growing and will continue to do. Their dividend growth averages 10%. He's adding shares.